In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 267 in vitro diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in in vitro diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading in vitro diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of in vitro diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of in vitro diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific in vitro diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in in vitro diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 267 in vitro diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in in vitro diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading in vitro diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of in vitro diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of in vitro diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific in vitro diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in in vitro diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits
This report provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse in vitro diagnostic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
The report is intended to provide the reader with an in-depth understanding of in vitro diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.The report includes:
- Trends in in vitro diagnostic dealmaking in the biopharma industry
- Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology
- The leading in vitro diagnostic deals by value
- Most active in vitro diagnostic licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - IntroductionChapter 6 - In vitro diagnostic dealmaking by technology type
Chapter 2 - Trends in in vitro diagnostic dealmaking
Chapter 3 - Leading in vitro diagnostic deals
Chapter 4 - Most active in vitro diagnostic dealmakers
Chapter 5 - In vitro diagnostic contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2cureX
- 3a-diagnostics
- 3M
- 10X Genomics
- 23andMe
- Abbott Laboratories
- Abingdon Health
- Abionic
- Accurate Diagnostic Laboratories
- Actelion
- Adaptive Phage Therapeutics
- Adeptrix
- Aegea Biotechnologies
- AEYE Health
- Afero
- Africa Centres for Disease Control and Prevention
- Africa Medical Supplies Platform
- Africa Union
- Agena Bioscience
- Agendia
- Agilent Technologies
- AIMA Laboratories
- Akribis Systems
- Alexion Pharmaceuticals
- Algenex
- AliveCor
- AllerGenis
- Allogene Therapeutics
- Alveo Technologies
- A Menarini Diagnostics
- American Type Culture Collection (ATCC)
- AMS
- Amydis
- Anixa Biosciences
- ANP Technologies
- Anteo Diagnostics
- Apollon Formularies
- Applied DNA Sciences
- Appriss Health
- Aptagen
- Aptitude Medical Systems
- Ares Genetics
- Armed Forces Medical Research Institute
- Arquer Diagnostics
- Asieris MediTech
- AssisTek
- AstraZeneca
- Asuragen
- Atomo Diagnostics
- Avacta
- Avalon GloboCare
- AvantGen
- Avrobio
- Babson Diagnostics
- Banyan Biomarkers
- BASF
- Battelle
- Baxter International
- Bayer
- BBI Solutions
- Beckman Coulter
- Becton Dickinson
- Beth Israel Deaconess Medical Center
- Bill and Melinda Gates Foundation
- Binx Health
- Bio-Rad Laboratories
- Bio-Techne
- bioAffinity Technologies
- BioCanna Healthcare
- Biocartis
- Biocept
- BioGen Medical
- BioGX
- BioIQ
- Biokit
- BioLight
- BioMarker Strategies
- Biomedical Advanced Research and Development Authority
- BIOMEDX Group
- bioMerieux
- BioSyntagma
- Biotage
- Bioventix
- Bird Foundation
- Bluejay Diagnostics
- Boehringer Ingelheim Vetmedica
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Bruker
- Cambridge Consultants
- CARB-X
- Cardiff University
- CardiNor
- CareDx
- Case Western Reserve University
- Cellgen Diagnostics
- CellSafe
- Centene
- Centers for Disease Control and Prevention
- Centogene
- Cepheid
- CerTest Biotec
- Cleveland Clinic
- Clinical Genomics
- Clinton Health Access Initiative
- CLX Health
- CND Life Sciences
- Collective Medical
- Columbia University
- Companion Medical
- Congenica
- Corvium
- CPT Medical
- CQuentia
- Cue Health
- Curative
- Cytiva
- CytoVale
- Cytox
- Dako
- DaRui Biotech
- DeepVerge
- Defense Advanced Research Projects Agency
- Department of Defense
- Department of Health and Human Services
- Devyser Diagnostics
- DexCom
- DiaSorin
- Diassess
- Digital Diagnostics
- Doping Control Center
- Eisai
- EKF Diagnostics (Germany)
- Ellume
- Empatica
- Enable Biosciences
- Endocanna Health
- Enzo Biochem
- Epizyme
- Erasmus University Medical Center
- Eureka Eurostars
- Eurofins LifeCodexx
- European Commission
- EverlyWell
- Evogen
- Exagen Diagnostics
- Expedeon
- Ez Sleep Technologies
- Fapon Biopharma
- Ferring Pharmaceuticals
- Fio
- FitBit
- Fluxergy
- Food and Drug Administration (FDA)
- Foresight Diagnostics
- Fortelinea Software Systems
- Foundation for Innovative New Diagnostics
- Fujirebio Diagnostics
- Fulgent Genetics
- G42 Healthcare
- GBS
- Genentech
- Geneseeq
- Gennova Biopharmaceuticals
- Genolution
- Genomic Health
- Genomics England
- Genomic Testing Cooperative
- Genomoncology
- GenScript Biotech
- GensKey Medical Technology
- George Washington University
- Getein Biotech
- Ginkgo BioWorks
- Global Access Diagnostics
- Global Dx
- Global Good Fund
- Global WholeHealth Partners
- Glooko
- Glytec
- GNA Biosolutions
- Greenfield Global
- Group K Diagnostics
- Guardant Health
- Gyros Protein Technologies
- Halodoc
- Hamilton Robotics
- Health Logic Interactive
- Health Network Laboratories
- HeartGenetics
- HelixBind
- Hememics Biotechnologies
- Hemex Health
- Henry M. Jackson Foundation
- HepQuant
- Hologic
- Hoowaki
- Horizon Europe
- Horizon Therapeutics
- Hoth Therapeutics
- Hvidovre Hospital
- ii Ventures
- Illumina
- ImmunArray
- Imperial College London
- Inagene Diagnostics
- Infectolab Americas
- Infinity BiologiX
- Inivata
- Innovation Zed
- Innovative Health Diagnostics
- Institut Curie
- Insulet
- Integrated Computer Solutions
- Invitae
- InVivoScribe
- Ionis Pharmaceuticals
- iRhythm Technology
- Jan Medical
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Research & Development
- Johns Hopkins University
- Johnson & Johnson Innovation
- Johnson & Johnson Vision
- John Wayne Cancer Institute
- Jubilant Radiopharma
- Kantaro Biosciences
- Kephera Diagnostics
- KingMed Diagnostics
- Kore
- L1 Systems
- Laboratory Corporation of America
- Lark Technologies
- LifeLabs Medical Laboratory Services
- LightDeck Therapeutics
- Liverpool School of Tropical Medicine
- Living Heart Foundation
- Livongo Health
- Longhorn Vaccines and Diagnostics
- Lucence
- Lucid Diagnostics
- Luminex
- Lumiphore
- LumiraDx
- Lunaphore
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Massachusetts Life Sciences Center
- Mass General Brigham
- Maxim Biomedical
- Mayo Clinic
- MBio Diagnostics
- MD Anderson Cancer Center
- Medibio
- Medical Marijuana
- Medical Research Foundation
- Medicinal Genomics
- Medigus
- Meenta
- Meihua International Medical Technologies
- MeMed
- Memorial Sloan Kettering Cancer Center
- Meridian Bioscience
- Mesa Biotech
- Metafora Biosystems
- Methapharm
- MicrobeDx
- Microdrop
- MicroGEM
- Minnesota Health System
- Mirimus
- Mologic
- Monsanto
- Motic
- Mount Sinai Health System
- MyHealthChecked
- Mylan Laboratories
- Nanommune
- NanoMosaic
- NanoPin Technologies
- Narayana Nethralaya Foundation
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
- National Institutes of Health
- National Research Council Canada
- National Science Foundation
- Navidea Biopharmaceuticals
- Navy Medical Research Centre
- Nemaura Medical
- Neogen
- Nephron Pharmaceuticals
- Neurotrack
- New Jersey Urology
- Newly Institute
- NGeneBio
- Nicoya
- Nimble Therapeutics
- Novartis
- Novoheart
- NOWDiagnostics
- Nucleix
- Numares
- Ohio State Innovation Foundation
- Ohio State University
- Oklahoma Medical Research Foundation
- Olive Labs
- OmeCare
- Omega Diagnostics Group
- Omixon
- OmniPathology
- One Drop
- Ontera
- Operon Technologies
- OraSure Technologies
- OrigiMed
- Ortho-Clinical Diagnostics
- Osteolabs
- Otsuka
- Owlstone Medical
- Oxford Immunotec
- Oxford Nanopore Technologies
- Oxgene
- PAI
- Pan Probe Biotech
- PAVmed
- PerkinElmer
- Personal Genome Diagnostics
- Perspectum Diagnostics
- Pfizer
- Phosphorus Genomics
- Photocure ASA
- Pillar Biosciences
- Precision Biomonitoring
- PredictImmune
- Prescient Medical
- Prevencio
- Primary Bio
- ProciseDx
- Progentec Diagnostics
- Providence Saint John's Health Center
- Public Health England
- Q-linea AB
- Qiagen
- QMC HealthID
- Quanterix
- QuantumDx
- Quest Diagnostics
- Quidel
- Rapid Dx Laboratory
- Relay Medical
- RenalytixAI
- Renegade Bio
- Revon Systems
- Roche
- Roche Diagnostics
- Roche Molecular Systems
- Royal Philips Electronics
- Saladax Biomedical
- Sansure Biotech
- Scanwell Health
- Seattle Childrens Research Institute
- Sebia
- Seegene
- Senseonics
- Sensible Medical Innovations
- Sensifree
- Seventh Sense Biosystems
- Shandong Yingsheng Biotechnology
- Sherlock Biosciences
- Siemens Healthineers
- SkylineDX
- Sona Nanotech
- Sorrento Therapeutics
- SpeeDx
- SQI Diagnostics
- Stanford University
- Stellar Technologies
- St Georges University of London
- Stone Diagnostics
- Stony Brook University
- Strados Labs
- Sumocor
- Symcel
- SystemOne
- Takara Bio USA
- Talis Biomedical
- Tangen Biosciences
- Tauriga Sciences
- TBG Management
- Techcyte
- Tempus
- The Native Antigen Company
- Theradiag
- Therma Bright
- Thermo Fisher Scientific
- Tika Diagnostics
- Topcon
- Total Testing Solutions
- TPMENA
- Tried & Tested
- True Diagnostics
- Tulane University
- Two Pore Guys
- U-Diagnostics
- U.K. Department for International Development
- Ubiquitome
- UCB
- United States Agency for International Development
- University College London
- University Hospital of Leuven
- University of Arkansas
- University of Glasgow
- University of Ottawa
- University of Oxford
- University of Sunderland
- University of Surrey
- University of Texas Health SCience Center at San Antonio
- US Army
- Vault Health
- Vela Diagnostics
- Velox Biosystems
- Veracyte
- Veravas
- Verily
- Virex Health
- Visby Medical
- VisionQuest Biomedical
- Visualant
- Vivera Pharmaceuticals
- VolitionRX
- Volk Optical
- VOTIS Subdermal Imaging Technologies
- Wellcome Trust
- WinterLight Labs
- Woom
- Wuhan Kindstar Diagnostics
- WuXi Biologics
- Wyss Institute
- XPhyto Therapeutics
- Yale School of Medicine
- Yale University
- Zora Biosciences
- zPREDICTA
- Zymo Research
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
